Sweden's Redsense Q4 net sales drop 52% on currency headwinds

About this update from Redsense Medical Ab

OverviewSweden-based medical device maker's Q4 net sales fell significantly yr/yrCompany reported Q4 operating loss amid restructuring and external challengesCompany granted regulatory approval for Clamp System in AustraliaOutlookRedsense aims to increase end-customer usage in the U.S. in 2026Company plans to launch Redsense Clamp in new markets outside the U.S.Redsense to implement revised pricing structure from February 2026Result DriversRESTRUCTURING IMPACT - Redsense's restructuring efforts aimed at operational alignment affected Q4 results, with a focus on long-term executionCURRENCY FLUCTUATIONS - Currency effects impacted Redsense's financial results, with USD/SEK fluctuations affecting reported figuresLOGISTICS CHALLENGES - Elevated logistics and customs costs affected gross margins, prompting a revised pricing structureKey DetailsMetricBeat/MissActualConsensus EstimateQ4 SalesSEK 6.04 mlnQ4 EPS-SEK 0.11Q4 Net Income-SEK 1.84 mlnQ4 EBIT-SEK 1.95 mlnPress Release: For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

View stock analysis, news, and events for Redsense Medical Ab